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Abstract – Recently, Dientamoeba fragilis has emerged as a signiﬁcant and common enteropathogen. The majority of
patients with dientamoebiasis present with gastrointestinal complaints and chronic symptoms are common. Numerous
studies have successfully demonstrated parasite clearance, coupled with complete resolution of clinical symptoms fol-
lowing treatment with various antiparasitic compounds. Despite this, there is very little in vitro susceptibility data avail-
able for the organism. Benzimidazoles are a class of antiparasitic drugs that are commonly used for the treatment of
protozoan and helminthic infections. Susceptibility testing was undertaken on four D. fragilis clinical isolates against
the following benzimidazoles: albendazole, ﬂubendazole, mebendazole, nocodazole, triclabendazole and thiabenda-
zole. The activities of the antiprotozoal compounds at concentrations ranging from 2 lg/mL to 500 lg/mL were deter-
mined via cell counts of D. fragilis grown in xenic culture. All tested drugs showed no efﬁcacy. The beta-tubulin
transcript was sequenced from two of the D. fragilis isolates and amino acid sequences predicted a susceptibility to
benzimidazoles. This is the ﬁrst study to report susceptibility proﬁles for benzimidazoles against D. fragilis, all of
which were not active against the organism. This study also found that beta-tubulin sequences cannot be used as a
reliable marker for resistance of benzimidazoles in D. fragilis.
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Re´sume´ – Activite´ des benzimidazoles contre Dientamoeba fragilis (Trichomonadida, Monocercomonadidae)
in vitro et corre´lation des se´quences de be´ta-tubuline comme indicateur de re´sistance. Re´cemment, D. fragilis
a e´merge´ comme un ente´ropathoge`ne important et commun. La majorite´ des patients avec dientamoebiase pre´sente
des troubles gastro-intestinaux et les symptoˆmes chroniques sont fre´quents. De nombreuses e´tudes ont de´montre´
avec succe`s l’e´limination des parasites, couple´e a` la re´solution comple`te des symptoˆmes cliniques, apre`s traitement
avec divers compose´s antiparasitaires. Malgre´ cela, il y a tre`s peu de donne´es disponibles sur la sensibilite´ in vitro
de cet organisme. Les benzimidazoles sont une classe de me´dicaments antiparasitaires qui sont couramment utilise´s
pour le traitement des infections a` protozoaires et helminthes. Les tests de sensibilite´ ont e´te´ re´alise´s sur quatre
isolats cliniques de D. fragilis avec les benzimidazoles suivants : albendazole, ﬂubendazole, me´bendazole,
nocodazole, triclabendazole et thiabendazole. Les activite´s des compose´s antiprotozoaires, a` des concentrations
allant de 2 lg/ml a` 500 lg/ml ont e´te´ de´termine´es par comptage de cellules de D. fragilis cultive´es en culture
xe´nique. Tous les me´dicaments teste´s n’ont montre´ aucune efﬁcacite´. Le transcript de be´ta-tubuline a e´te´ se´quence´
a` partir de deux isolats de D. fragilis, et les se´quences d’acides amine´s pre´disaient une sensibilite´ aux
benzimidazoles. Cette e´tude est la premie`re a` signaler des proﬁls de sensibilite´ pour les benzimidazoles contre
D. fragilis, qui tous e´taient non actifs contre l’organisme. Cette e´tude a e´galement re´ve´le´ que les se´quences de
be´ta-tubuline ne peuvent pas eˆtre utilise´es comme un marqueur ﬁable de la re´sistance de benzimidazoles chez
D. fragilis.
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Introduction
Dientamoeba fragilis Jepps and Dobell, 1918 [18] is a pro-
tozoan parasite that is the only recognised species in the genus
Dientamoeba. It is classiﬁed as a trichomonad in the class
Trichomonadida and has been shown to be closely related to
the amoeboﬂagellate Histomonas meleagridis [14]. Dienta-
moeba is emerging as one of the most commonly encountered
enteric protozoa of humans with prevalence reaching up to 43%
in some studies when appropriate diagnostic methods are uti-
lised [27]. Despite this, it continues to be neglected as a signif-
icant pathogen, with many laboratories not routinely
performing adequate laboratory diagnostic testing for the para-
site [2, 7, 12].
The clinical presentation of dientamoebiasis varies from
asymptomatic carriage to symptomatic presentations, ranging
from altered bowel motions, abdominal discomfort, nausea,
and diarrhoea [28, 29, 33, 35]. The propensity of the organism
to cause chronic symptoms, ranging from weeks to months, has
been reported in the scientiﬁc literature [7, 15]. The life cycle
and mode of transmission of D. fragilis are poorly deﬁned.
However, the recent discovery of a cyst stage in the life cycle
of this parasite would suggest that direct transmission via the
faecal-oral route is the most likely mode of transmission [24].
High rates of transmission between close contacts and house-
hold members have been described, highlighting the transmissi-
ble nature of the organism [31].
Despite the discovery of the parasite nearly 100 years ago
and the abundance of reports in the scientiﬁc literature
regarding infections, very little research has been conducted
on the use of suitable antimicrobial compounds to control infec-
tions and subsequent susceptibility testing of isolates [32]. Only
three studies to date have undertaken in vitro susceptibility test-
ing on D. fragilis isolates [3, 10, 25], and no studies to date
have looked at the efﬁcacy of the benzimidazoles. Benzimidaz-
oles have been shown to be effective in treating both
Trichomonas vaginalis [20, 21] and Giardia intestinalis [38]
and ineffective against H. meleagridis [9, 17]. Benzimidazoles
are a class of antiparasitic drug [5], which act on beta-tubulin by
binding to a high-afﬁnity binding site on the beta-tubulin mono-
mer [22]. There are several different beta-tubulin residues that
have been proposed as indicators of benzimidazole susceptibil-
ity. In protozoa, two residues, Glu-198 and Phe-200, have been
hypothesised as an indicator for susceptibility [13, 21].
In Trichomonad parasites, agreement between beta-tubulin
sequences and susceptibility to benzimidazoles in vitro has been
established for T. vaginalis [20, 21]. However, a study on
H. meleagridis found that while histomonal amino acid
sequences predicted a susceptibility to benzimidazoles, no cor-
relation was found with in vitro activity for these agents [16].
The aim of this study was to test the in vitro activity of
albendazole, ﬂubendazole, mebendazole, nocodazole, triclaben-
dazole and thiabendazole against clinical isolates of D. fragilis
and to determine whether beta-tubulin sequences can be used as
an indicator for benzimidazole susceptibility in protozoa.
Materials and methods
Parasite culture
Four strains of D. fragilis were isolated and propagated
in vitro using a biphasic xenic culture system using a Loefﬂer’s
slope medium modiﬁed from a previously published
method [6] consisting of an inspissated horse serum slope over-
laid with 5 mL of PBS and supplemented with 2–5 mg of rice
starch.
Genotyping of D. fragilis strains
Genotyping was performed as previously described target-
ing the SSU rRNA gene [30].
Antimicrobial agents and susceptibility testing
The following antimicrobial agents were used in suscepti-
bility testing: albendazole, ﬂubendazole, mebendazole, noco-
dazole, triclabendazole and thiabendazole (Sigma-Aldrich,
Australia). All benzimidazoles were supplied in powdered form
and dissolved in dimethylsulfoxide (DMSO) to make stock
solutions of 5 mg/mL. Further doubling dilutions (PBS) were
prepared from 1,000 lg/mL to 4 lg/mL. The respective dilu-
tions were added to the PBS overlay at a 1:1 ratio to a ﬁnal vol-
ume of 5 mL, giving a ﬁnal dilution range of 500 lg/mL to
2 lg/mL of antimicrobial agent in the media. All susceptibility
testing was performed in triplicate. A control consisting of
1 mL of 10% DMSO diluted (PBS) into a total of 5 mL and
then doubling dilutions were performed (in triplicate) for all
drugs to rule out inhibitory effects of DMSO on D. fragilis.
The cell concentrations were determined using Kova slides
viewed under phase-contrast microscopy at a magniﬁcation of
X400. Susceptibility testing with each compound was per-
formed over 4 days. Minimum lethal concentrations (MLCs)
were determined to be the concentration of the drug at which
no trophozoites were observed. A control consisting of a benz-
imidazole sensitive strain of Trichomonas vaginalis (isolated
from a local clinical sample) was used to ascertain efﬁcacy of
the antimicrobial agents tested (albendazole, ﬂubendazole,
mebendazole, nocodazole, triclabendazole and thiabendazole)
as previously described [37]. A positive control was also
included consisting of the D. fragilis cells and the reference
drug metronidazole (Sigma Aldrich, Australia) as previously
described [24].
RNA extraction for molecular analysis
Two of the four isolates of Dientamoeba used in the suscep-
tibility testing experiments underwent further molecular testing.
Ribonucleic acid was extracted from culture sediments using
TRIsure reagent (Bioline, catalogue number BIO-38032) and
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enriched for eukaryotic mRNA using oligo (dT)-cellulose chro-
matography. Sequencing of the transcriptome was performed
by the service provider AGRF (http://agrf.org.au/). The meth-
ods used to sequence and assemble the transcriptome of
D. fragilis will be published elsewhere.
Mining the transcriptome for tubulin sequences
Contigs from the D. fragilis transcriptome were used to
construct a blast database using the makeblastdb program
available from the NCBI website. Histomonas meleagridis
beta-tubulin 1, (GenBank accession no.: AEN84279) was used
as a query sequence in a tblastn search (default parameters, ver-
sion 2.2.28+) against this database to identify homologues
within the D. fragilis transcriptome. Putative D. fragilis beta-
tubulin sequences detected in this blast search were then sub-
jected to blastn and blastx searches against the NCBI nucleotide
and protein databases, respectively, to conﬁrm their identity.
Putative D. fragilis beta-tubulins were translated into their
protein sequences using the ‘‘Translate’’ component of
the ‘‘Sequence manipulation suite’’ (Stothard 2000) (website:
http://www.bioinformatics.org/sms2/translate.html). Alignments




All four D. fragilis strains used in the experiments were
identiﬁed as genotype 1.
MLCs
All benzimidazoles tested (albendazole, ﬂubendazole,
mebendazole, nocodazole, triclabendazole and thiabendazole)
had no effect on the in vitro D. fragilis cultures with MLCs
of >500 lg/mL. Metronidazole, however, was effective with
an MLC of 31 lg/mL. The T. vaginalis control strain was
susceptible to all benzimidazoles with MLCs ranging from 4
to 16 lg/mL. Thus, the observed lack of activity against
D. fragilis is not due to benzimidazole degradation at any point
during the experiment.
Identification of beta-tubulin transcripts
in the D. fragilis transcriptome
Three D. fragilis contigs from D. fragilis isolate 1 were
identiﬁed as close homologues of H. meleagridis beta-tubulin
(GenBank accession no.: AEN84279) by tblastn search. How-
ever, only two of these could be translated into a full length
tubulin amino acid sequence. The two full length tubulin con-
tigs achieved signiﬁcant blastn and blastx hits to beta-tubulin
sequences from other trichomonads when blasted against the
NCBI web server, conﬁrming that at least two beta-tubulin iso-
forms are present in D. fragilis. These two D. fragilis beta-
tubulin sequences can be found in GenBank under accession
nos. KM186141 and KM186142.
Examination for amino acids predictive
of albendazole susceptibility
Alignment of D. fragilis amino acid sequences of beta-
tubulin 1 and 2 to beta-tubulins from other Trichomonads
(Fig. 1) conﬁrmed that D. fragilis possesses the amino acids
which are predictive of albendazole susceptibility. Based on
these alignments, it became apparent that Trichomonad beta-
tubulins possess an additional valine residue which follows
the ﬁrst methionine amino acid. This valine residue was not
present in other beta-tubulin sequences examined (such as
Candida sp., Aspergillus sp. and Ascaris sp – data not shown)
and the implications of this are that the amino acids predictive
for albendazole susceptibility are moved forward by one addi-
tional position (see Fig. 1), compared to previous reports
describing beta-tubulin sequences [16, 21].
Based on the results of the current study, amino acid
positions 198 (199 for Trichomonads) and 200 (201 for
Trichomonads) cannot be used as predictors of albendazole
resistance (or susceptibility). We suggest, therefore, that there
may be other amino acids in the beta-tubulin protein which
may be predictive of albendazole susceptibility in protozoa.
Alternatively, it may be that the beta-tubulin sequence alone
cannot be used as a reliable predictor for albendazole resistance
(or susceptibility) in protozoa.
Discussion
Dientamoeba is a frequently encountered enteric protozoan,
yet despite the relatively high prevalence of this organism
[2, 27], very little research has been undertaken on susceptibil-
ity testing to drugs. There is no gold standard treatment for
D. fragilis, and the majority of treatment data is based on a
small number of case reports [26]. Many cases of treatment
failure have been reported [4, 28, 36] leading some researchers
to postulate that current treatment options may be suboptimal
for the eradication of Dientamoeba [26]. This highlights the
need for further study on antiprotozoal agents that have
potential activity against D. fragilis. While Dientamoeba can
be readily cultured from fresh un-refrigerated clinical samples,
long-term cultures have been shown to be notoriously difﬁcult
to maintain [23]. This has hampered many in vitro studies of
this organism in particular susceptibility testing. However,
recent advances in culturing techniques have allowed for
long-term subculture of isolates [6, 23].
Current data is lacking on susceptibility proﬁles for
D. fragilis isolates with only three previous studies conducted
to date [3, 10, 25]. Only two of these used clinical samples,
with one using the no longer available D. fragilis ATCC strain
30948 which was of the rarely encountered genotype 2 type,
which is not the predominant genotype found in clinical
samples [30]. The current study used four clinical isolates of
D. fragilis, all of which were genotype 1.
Benzimidazoles have been widely used since the 1960s as
anthelmintic agents in veterinary and human medicine and as
antifungal agents in agriculture. Initially, benzimidazole activity
seemed to be limited to helminths and fungi however in 1985
T. vaginalis was reported to be inhibited by the benzimidazole
derivatives mebendazole and ﬂubendazole [19]. Subsequently,
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susceptibility of benzimidazoles was shown for G. intestinalis
and microsporidia [21]. More recently, the activity of benzimi-
dazoles was tested against H. meleagridis and they were shown
to be an ineffective agent for treatment in vitro [16]. Resistance
to the benzimidazoles has been observed in parasitic nematodes
of livestock animals since the early 1960s [11]. The beta-tubulin
protein confers benzimidazole sensitivity in the helminth
Caenorhabditis elegans and clear evidence exists that three
different single amino acid substitutions (Thr-167, Glu-198
and Phe-200) in the beta-tubulin protein of different nematode
Figure 1. Full alignment of beta-tubulin amino acid sequences from D. fragilis with tubulin sequences derived from Trichomonads and other
eukaryotes. The residues highlighted blue are those thought to be predictors of albendazole susceptibility in protozoa as described in previous studies.
Amino acids shaded yellow represent the most common amino acid at that position (predicted consensus based on this alignment). Amino acids
shaded orange are those which differ from the predicted consensus. Note however that at positions 8, 430, 434 and 446, a consensus cannot be
resolved. TV: Trichomonas vaginalis, DF: Dientamoeba fragilis, HM: Histomonas meleagridis, TF: Tritrichomonas foetus, HS: Homo sapiens,
DR: Danio rerio. For Histomonas meleagridis and Trichomonas vaginalis the species acronym is followed by the corresponding UniprotKB
identiﬁer. For all other organisms, the species acronym is followed by the corresponding Genbank accession number.
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species can be responsible, each leading separately to resistance
[8]. However in protists, it seems that only two may play a role,
namely Glu-198 and Phe-200 [21].
Although the complete crystallographic structure of the
beta-tubulin monomer and the mechanism of action of
benzimidazoles are still unknown, a recent study used
homology modelling techniques along with molecular docking
studies to advance this area of research [1]. The study was
undertaken on Trichinella spiralis and the researchers were able
to suggest a binding site for benzimidazoles that contains sev-
eral amino acids associated with resistance (Phe-167, Glu-198
and Phe-200). This further supports the role of these amino
acid positions in albendazole resistance or susceptibility in
helminths.
The current study used several benzimidazole derivatives:
albendazole, ﬂubendazole, mebendazole, nocodazole, triclaben-
dazole and thiabendazole. All were shown to be ineffective
anti-Dientamoeba agents. Concentrations ranging from 2 lg/
mL to 500 lg/mL resulted in D. fragilis trophozoite cell counts
similar to that of the control. Although both Giardia and
Trichomonas have been shown to be susceptible to benzimidaz-
oles, the closely related H. meleagridis was shown to be resis-
tant to benzimidazoles [9, 16, 17]. The exact mechanism for
resistance is however unknown [16].
Based on this study, positions 198 and 200 of the beta-
tubulin protein are not predictive of albendazole resistance,
indicating that we need to look elsewhere to understand the phe-
nomenon of resistance to benzimidazoles in Trichomonads.
It should also be noted that this phenomena has not only been
reported in Trichomonads. Giardia strains can reportedly
become resistant to albendazole without having mutations in
Glu-198 or Phe-200 [34]. Taken with the results of the current
study, this detracts from the importance of Glu-198 and
Phe-200 in albendazole susceptibility as seen in protozoa.
Clearly, other mechanisms of albendazole resistance must be
explored in protozoa.
Conclusion
The results of this study show that benzimidazoles have no
effect onD. fragilis in culture. As such, no therapeutic response
could be expected from the treatment of dientamoebiasis with
benzimidazoles. The preliminary data presented would also sug-
gest that beta-tubulin sequences cannot be used as a reliablemar-
ker for resistance of benzimidazoles inD. fragilis and as a result,
other markers of benzimidazole resistance need to be explored.
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